Hemophilia A Without Inhibitor
8
2
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
38%
3 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Pharmacokinetic-guided Dosing of Emicizumab
The Hemophilia Inhibitor Prevention Trial
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A